Click on the subcategory below to find drug monographs for that particular area.
For women with stage I or II breast cancer without a BRCA mutation, contralateral prophylactic mastectomy (CPM) is associated with an absolute 20-year survival benefit of <1%.
For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age.
The FDA has approved Zydelig (idelalisib; Gilead Sciences) for relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL).
Puma Biotechnology announced results from its Phase 3 ExteNET trial of neratinib (PB272) for the extended adjuvant treatment of breast cancer.
Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
The Brigham Board Review in Hematology and Oncology offers expert preparation for your ABIM subspecialty ...
This activity can help oncology nurses refresh their knowledge of the risks and treatments for ...
Nurse awareness of this treatment option and the patient selection criteria may be a significant ...